Matthias H. Tschöp

Jul 25, 2024 | cell.com | Christine M. Kusminski |Diego Perez-Tilve |Richard D. DiMarchi |Matthias H. Tschöp

Dale C.E. Fatemifar G. Palmer T.M. White J. Prieto-Merino D. Zabaneh D. Engmann J.E.L. Shah T. Wong A. Warren H.R. et al. Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. Circulation. 2017; 135: 2373-2388https://doi.org/10.1161/CIRCULATIONAHA.116.026560Islami F. Goding Sauer A. Gapstur S.M. Jemal A. Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015.

Aug 16, 2023 | cell.com | Jonathan E. Campbell |Brian Finan |Richard D. DiMarchi |Matthias H. Tschöp

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Jun 12, 2023 | nature.com | Rubén Nogueiras |Michael A. Nauck |Matthias H. Tschöp

AbstractThe discovery and development of so-called gut hormone co-agonists as a new class of drugs for the treatment of diabetes and obesity is considered a transformative breakthrough in the field. Combining action profiles of multiple gastrointestinal hormones within a single molecule, these novel therapeutics achieve synergistic metabolic benefits. The first such compound, reported in 2009, was based on balanced co-agonism at glucagon and glucagon-like peptide-1 (GLP-1) receptors.